Abstract
Approximately seventy patients undergo solid organ transplantation (SOT) every day in the United States. Sepsis remains the first or second most common cause of death in transplant recipients, depending on the allograft type. The rapid diagnosis and treatment of sepsis is critical to ensure improved survival outcome in this special patient population. However, these patients frequently lack the classic systemic inflammatory response syndrome (SIRS), commonly seen in the immunocompetent patients. In order to minimize delays in the diagnosis of sepsis in SOT recipients, it is paramount to recognize the specific risk factors for infection associated with each allograft type. In addition, the particular surgical techniques involved in each type of transplantation may be closely related to the clinical manifestations of the infection process. This correlation can further advance the diagnosis and treatment of sepsis. In conclusion, precocious diagnosis, rapid initiation of antibiotics, surgical correction when necessary, and reduction of immunosuppression, are the mainstream approach to sepsis in the SOT patient. The recent developments in severe sepsis are discussed in the context of the transplant recipient.
Keywords: systemic inflammatory response syndrome (SIRS), Cytomegalovirus, Pseudomonas aeruginosa, immunosuppression, antibiotic
Current Drug Targets
Title: Sepsis and Solid Organ Transplantation
Volume: 8 Issue: 4
Author(s): A. C. Kalil, H. Dakroub and A. G. Freifeld
Affiliation:
Keywords: systemic inflammatory response syndrome (SIRS), Cytomegalovirus, Pseudomonas aeruginosa, immunosuppression, antibiotic
Abstract: Approximately seventy patients undergo solid organ transplantation (SOT) every day in the United States. Sepsis remains the first or second most common cause of death in transplant recipients, depending on the allograft type. The rapid diagnosis and treatment of sepsis is critical to ensure improved survival outcome in this special patient population. However, these patients frequently lack the classic systemic inflammatory response syndrome (SIRS), commonly seen in the immunocompetent patients. In order to minimize delays in the diagnosis of sepsis in SOT recipients, it is paramount to recognize the specific risk factors for infection associated with each allograft type. In addition, the particular surgical techniques involved in each type of transplantation may be closely related to the clinical manifestations of the infection process. This correlation can further advance the diagnosis and treatment of sepsis. In conclusion, precocious diagnosis, rapid initiation of antibiotics, surgical correction when necessary, and reduction of immunosuppression, are the mainstream approach to sepsis in the SOT patient. The recent developments in severe sepsis are discussed in the context of the transplant recipient.
Export Options
About this article
Cite this article as:
Kalil C. A., Dakroub H. and Freifeld G. A., Sepsis and Solid Organ Transplantation, Current Drug Targets 2007; 8 (4) . https://dx.doi.org/10.2174/138945007780362746
DOI https://dx.doi.org/10.2174/138945007780362746 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Increased Serum HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients
Current Vascular Pharmacology Acute Kidney Injury: Turning the Tide
Current Drug Targets Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease
Current Neurovascular Research The Multifunctional Protein C System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Recent Patents on Biotechnology Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents
Current Drug Metabolism Heme Oxygenase-1 in Lung Disease
Current Drug Targets Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome
Recent Advances in Inflammation & Allergy Drug Discovery DNA Damage and Repair in the Brain After Cerebral Ischemia
Current Topics in Medicinal Chemistry The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The No-Reflow Phenomenon in the Coronary Circulation
Cardiovascular & Hematological Agents in Medicinal Chemistry Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued)